New Delhi: Noting the possible risk of expected adverse effects in healthy subjects, the Subject Expert Committee (SEC), functioning under the Central Drug Standard Control Organization (CDSCO), has declined to recommend a proposed clinical study by Advity Research Private Limited for Fludrocortisone Tablets USP 0.2 mg.

This came after the firm presented the protocol along with published literature of Fludrocortisone Tablet USP 0.2 mg, in light of the earlier SEC recommendation dated 07.08.25.

Fludrocortisone is a mineralocorticoid used to treat adrenocortical insufficiency and salt-losing adrenogenital syndrome.

The main endogenous mineralocorticoid, aldosterone, is produced in the zona glomerulosa of the adrenal cortex—it acts on mineralocorticoid receptors in the kidneys to increase

See Full Page